Literature DB >> 26408071

The prosocial effects of 3,4-methylenedioxymethamphetamine (MDMA): Controlled studies in humans and laboratory animals.

Philip Kamilar-Britt1, Gillinder Bedi2.   

Abstract

Users of ±3,4-methylenedioxymethamphetamine (MDMA; 'ecstasy') report prosocial effects such as sociability and empathy. Supporting these apparently unique social effects, data from controlled laboratory studies indicate that MDMA alters social feelings, information processing, and behavior in humans, and social behavior in rodents. Here, we review this growing body of evidence. In rodents, MDMA increases passive prosocial behavior (adjacent lying) and social reward while decreasing aggression, effects that may involve serotonin 1A receptor mediated oxytocin release interacting with vasopressin receptor 1A. In humans, MDMA increases plasma oxytocin and produces feelings of social affiliation. It decreases identification of negative facial expressions (cognitive empathy) and blunts responses to social rejection, while enhancing responses to others' positive emotions (emotional empathy) and increasing social approach. Thus, consistent with drug folklore, laboratory administration of MDMA robustly alters social processing in humans and increases social approach in humans and animals. Effects are consistent with increased sociability, with mixed evidence about enhanced empathy. These neurobiologically-complex prosocial effects likely motivate recreational ecstasy use.
Copyright © 2015. Published by Elsevier Ltd.

Entities:  

Keywords:  Ecstasy; Empathy; MDMA; Molly; Prosocial; Sociability; Social reward; Social threat

Mesh:

Substances:

Year:  2015        PMID: 26408071      PMCID: PMC4678620          DOI: 10.1016/j.neubiorev.2015.08.016

Source DB:  PubMed          Journal:  Neurosci Biobehav Rev        ISSN: 0149-7634            Impact factor:   8.989


  94 in total

1.  'Ecstasy' as a social drug: MDMA preferentially affects responses to emotional stimuli with social content.

Authors:  Margaret C Wardle; Matthew G Kirkpatrick; Harriet de Wit
Journal:  Soc Cogn Affect Neurosci       Date:  2014-03-27       Impact factor: 3.436

2.  Increased oxytocin concentrations and prosocial feelings in humans after ecstasy (3,4-methylenedioxymethamphetamine) administration.

Authors:  G J H Dumont; F C G J Sweep; R van der Steen; R Hermsen; A R T Donders; D J Touw; J M A van Gerven; J K Buitelaar; R J Verkes
Journal:  Soc Neurosci       Date:  2009       Impact factor: 2.083

3.  Psychological and physiological effects of MDMA ("Ecstasy") after pretreatment with the 5-HT(2) antagonist ketanserin in healthy humans.

Authors:  M E Liechti; M R Saur; A Gamma; D Hell; F X Vollenweider
Journal:  Neuropsychopharmacology       Date:  2000-10       Impact factor: 7.853

4.  Is ecstasy an "empathogen"? Effects of ±3,4-methylenedioxymethamphetamine on prosocial feelings and identification of emotional states in others.

Authors:  Gillinder Bedi; David Hyman; Harriet de Wit
Journal:  Biol Psychiatry       Date:  2010-10-14       Impact factor: 13.382

5.  Acute prosocial effects of oxytocin and vasopressin when given alone or in combination with 3,4-methylenedioxymethamphetamine in rats: involvement of the V1A receptor.

Authors:  Linnet Ramos; Callum Hicks; Richard Kevin; Alex Caminer; Rajeshwar Narlawar; Michael Kassiou; Iain S McGregor
Journal:  Neuropsychopharmacology       Date:  2013-05-16       Impact factor: 7.853

6.  Cerebrospinal fluid oxytocin, life history of aggression, and personality disorder.

Authors:  Royce Lee; Craig Ferris; L D Van de Kar; Emil F Coccaro
Journal:  Psychoneuroendocrinology       Date:  2009-07-03       Impact factor: 4.905

7.  Increased positive versus negative affective perception and memory in healthy volunteers following selective serotonin and norepinephrine reuptake inhibition.

Authors:  Catherine J Harmer; Nicholas C Shelley; Philip J Cowen; Guy M Goodwin
Journal:  Am J Psychiatry       Date:  2004-07       Impact factor: 18.112

8.  Quitting ecstasy: an investigation of why people stop taking the drug and their subsequent mental health.

Authors:  Suzanne L Verheyden; Rachel Maidment; H Valerie Curran
Journal:  J Psychopharmacol       Date:  2003-12       Impact factor: 4.153

9.  The safety and efficacy of {+/-}3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study.

Authors:  Michael C Mithoefer; Mark T Wagner; Ann T Mithoefer; Lisa Jerome; Rick Doblin
Journal:  J Psychopharmacol       Date:  2010-07-19       Impact factor: 4.153

10.  Harms and benefits associated with psychoactive drugs: findings of an international survey of active drug users.

Authors:  Celia J A Morgan; Louise A Noronha; Mark Muetzelfeldt; Amanda Feilding; Amanda Fielding; H Valerie Curran
Journal:  J Psychopharmacol       Date:  2013-02-25       Impact factor: 4.153

View more
  46 in total

Review 1.  REBUS and the Anarchic Brain: Toward a Unified Model of the Brain Action of Psychedelics.

Authors:  R L Carhart-Harris; K J Friston
Journal:  Pharmacol Rev       Date:  2019-07       Impact factor: 25.468

Review 2.  A review of the effects of nicotine on social functioning.

Authors:  Lea M Martin; Michael A Sayette
Journal:  Exp Clin Psychopharmacol       Date:  2018-06-28       Impact factor: 3.157

Review 3.  Dark Classics in Chemical Neuroscience: 3,4-Methylenedioxymethamphetamine.

Authors:  Lee E Dunlap; Anne M Andrews; David E Olson
Journal:  ACS Chem Neurosci       Date:  2018-07-12       Impact factor: 4.418

4.  3,4-Methylenedioxymethamphetamine Increases Affiliative Behaviors in Squirrel Monkeys in a Serotonin 2A Receptor-Dependent Manner.

Authors:  Elizabeth G Pitts; Adelaide R Minerva; Erika B Chandler; Jordan N Kohn; Meghan T Logun; Agnieszka Sulima; Kenner C Rice; Leonard L Howell
Journal:  Neuropsychopharmacology       Date:  2017-04-20       Impact factor: 7.853

Review 5.  Clinical applications of hallucinogens: A review.

Authors:  Albert Garcia-Romeu; Brennan Kersgaard; Peter H Addy
Journal:  Exp Clin Psychopharmacol       Date:  2016-08       Impact factor: 3.157

6.  Separating the agony from ecstasy: R(-)-3,4-methylenedioxymethamphetamine has prosocial and therapeutic-like effects without signs of neurotoxicity in mice.

Authors:  Daniel W Curry; Matthew B Young; Andrew N Tran; Georges E Daoud; Leonard L Howell
Journal:  Neuropharmacology       Date:  2017-10-06       Impact factor: 5.250

7.  The 2014 Philip S. Portoghese Medicinal Chemistry Lectureship: The "Phenylalkylaminome" with a Focus on Selected Drugs of Abuse.

Authors:  Richard A Glennon
Journal:  J Med Chem       Date:  2017-03-15       Impact factor: 7.446

8.  MDMA does not alter responses to the Trier Social Stress Test in humans.

Authors:  Anya K Bershad; Melissa A Miller; Harriet de Wit
Journal:  Psychopharmacology (Berl)       Date:  2017-04-21       Impact factor: 4.530

Review 9.  Progress and promise for the MDMA drug development program.

Authors:  Allison A Feduccia; Julie Holland; Michael C Mithoefer
Journal:  Psychopharmacology (Berl)       Date:  2017-11-20       Impact factor: 4.530

Review 10.  (±)-MDMA and its enantiomers: potential therapeutic advantages of R(-)-MDMA.

Authors:  Elizabeth G Pitts; Daniel W Curry; Karly N Hampshire; Matthew B Young; Leonard L Howell
Journal:  Psychopharmacology (Berl)       Date:  2017-12-16       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.